<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="glofitamab-tp53-rrdlbcl-zhao-pb3271">
    <meta name="study:title" content="PB3271 - Glofitamab chemo-free regimens in TP53-mutated R/R DLBCL">
    <meta name="study:fileName" content="Abstracts/PB3271-Glofitamab-TP53-RRDLBCL-Zhao.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="3L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Glofitamab,Bispecific antibodies,Acalabrutinib,Zanubrutinib,Obutinib,BTK inhibitors,Sintilimab,PD-1 inhibitor,Lenalidomide,Immunomodulatory drugs,Polatuzumab Vedotin,ADC">

    <title>PB3271: Glofitamab Chemo-Free Regimens in TP53-mutated R/R DLBCL (Zhao) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3271 - Glofitamab Chemo-Free Regimens in TP53-mutated R/R DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)">
                        <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=20)</h4>
                    <p>R/R DLBCL Pts with TP53 mutations. Aim: Efficacy & safety of chemo-free Glofitamab combos.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 64 64" fill="var(--sobi-teal)">
                        <path d="M32 60 V40 M20 40 L32 40 L44 40 M20 40 L12 28 L4 20 M44 40 L52 28 L60 20 M12 28 L16 24 M52 28 L48 24" stroke="var(--sobi-teal)" stroke-width="5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
                        <circle cx="4" cy="20" r="3" fill="var(--sobi-orange)"/><circle cx="60" cy="20" r="3" fill="var(--sobi-yellow)"/>
                    </svg>
                    <h4>Intervention</h4>
                    <p>Glofitamab + (BTKi / Sintilimab / Lenalidomide / Polatuzumab Vedotin). Real-world data.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (N=15 eval.)</h4>
                    <p>ORR: <span class="highlight-value">66.7%</span><br>CRR: <span class="highlight-value">40.0%</span> (at end of 6th cycle)</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)">
                        <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Generally mild AEs (G1/2 CRS, tumor flare). High efficacy & good tolerability in this high-risk group.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3271 - Chemo-free regimens containing Glofitamab are significantly beneficial for relapsed/refractory diffuse large B cell lymphoma patients with TP53 gene mutations: Real-world data from multi-centers in China</h1>
            <p class="abstract-sub-header">Xia Zhao, Zhihe Liu, Junqing Xu, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3271 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>TP53 gene mutations are an independent risk factor for the overall survival of patients with diffuse large B cell lymphoma (DLBCL), even with 1L R-CHOP or Pola-R-CHP.</li>
                        <li>Relapse/refractory episodes are common in these patients.</li>
                        <li>No standard regimen exists for R/R DLBCL patients with TP53 gene mutations.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To investigate the clinical efficacy and adverse events of chemo-free regimens containing glofitamab for patients with R/R DLBCL with TP53 gene mutations.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Retrospective, multi-center study (3 hospitals in China).</li>
                        <li>Enrollment period: April 2024 - February 2025.</li>
                        <li>Patients: R/R DLBCL with TP53 gene mutations (exons 5-8 detected by NGS).</li>
                        <li>Intervention: Chemo-free regimens containing glofitamab combined with:
                            <ul class="list-circle list-inside ml-4">
                                <li>BTK inhibitors (acalabrutinib, zanubrutinib, or obutinib)</li>
                                <li>Sintilimab (PD-1 inhibitor)</li>
                                <li>Lenalidomide</li>
                                <li>Polatuzumab vedotin</li>
                            </ul>
                        </li>
                        <li>Response assessment: PET-CT by local investigators.</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">Study Overview: Glofitamab Chemo-Free Combos in TP53mut R/R DLBCL</h3>
                        <div class="schema-enrollment">
                            <strong>R/R DLBCL Patients with TP53 Mutations (N=20)</strong>
                            <span>(3 Chinese Hospitals, Apr 2024 - Feb 2025)</span>
                        </div>
                        <div class="schema-arrow-down">â–¼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-gray-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Treatment Regimens Received:</strong>
                                <span>Glofitamab + One of:</span>
                                <ul class="list-disc list-inside text-xs text-left mx-auto mt-1 w-max">
                                    <li>BTK inhibitors (Acalabrutinib, Zanubrutinib, Obutinib)</li>
                                    <li>Sintilimab (PD-1 inhibitor)</li>
                                    <li>Lenalidomide</li>
                                    <li>Polatuzumab Vedotin</li>
                                </ul>
                                <span class="text-xs mt-1">(Median 6 cycles Glofitamab)</span>
                            </div>
                        </div>
                        <div class="schema-assessment-points">
                           <span>Safety (Adverse Events)</span>
                           <span>Efficacy (ORR, CRR by PET-CT)</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=20)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>66 (29-79)</td></tr>
                                <tr><td>Male : Female Ratio</td><td>3:1</td></tr>
                                <tr><td>Median Prior Chemotherapy Lines (range)</td><td>4 (Abstract implies range, not given)</td></tr>
                                <tr><td>Ann Arbor Stage III/IV, n (%)</td><td>20 (100%)</td></tr>
                                <tr><td>IPI Score â‰¥3, n (%)</td><td>13 (65.0%)</td></tr>
                                <tr><td>â‰¥2 Extranodal Lesions, n (%)</td><td>16 (80.0%)</td></tr>
                                <tr><td>Non-GCB (Hans), n (%)</td><td>17 (85.0%)</td></tr>
                                <tr><td>Median Ki-67, % (range)</td><td>90% (70-90%)</td></tr>
                                <tr><td>Double-Expressor Lymphoma, n (%)</td><td>11 (55.0%)</td></tr>
                                <tr><td>Common TP53 Mutation Position</td><td>Exon 5 and 7</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Treatment Details (N=20)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Median number of glofitamab treatment cycles: 6 (range 3-12).</li>
                        <li><strong>Glofitamab Combinations Received:</strong>
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li>+ BTK inhibitors (acalabrutinib, zanubrutinib, or obutinib): 10 pts</li>
                                <li>+ Sintilimab: 2 pts</li>
                                <li>+ Lenalidomide: 6 pts</li>
                                <li>+ Polatuzumab vedotin: 2 pts</li>
                            </ul>
                        </li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (N=15 Evaluable Pts*)</h2>
                     <p class="text-xs meta-info mb-2">*Patients who completed at least 6 cycles of glofitamab.</p>
                    <div class="grid grid-cols-1 sm:grid-cols-2 gap-4 mb-4">
                        <div class="infographic-item orange-theme">
                            <div class="infographic-icon icon-orange">ðŸ“Š</div>
                            <div class="infographic-value">66.7%</div>
                            <div class="infographic-label">Overall Response Rate (ORR)</div>
                        </div>
                        <div class="infographic-item teal-theme">
                            <div class="infographic-icon icon-teal">ðŸŽ¯</div>
                            <div class="infographic-value">40.0%</div>
                            <div class="infographic-label">Complete Response Rate (CRR)</div>
                        </div>
                    </div>
                    <div class="chart-container mb-6">
                        <svg id="glofitamabTp53ResponseChart" width="350" height="300"></svg>
                        <div id="glofitamabTp53ResponseLegend" class="legend"></div>
                    </div>
                     <p class="text-sm text-center">Response assessed at the end of the sixth cycle.</p>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Safety Summary (N=20)</h2>
            <p class="text-sm">Adverse events were generally mild.</p>
            <p class="text-sm mt-2"><strong>Most Common Adverse Events:</strong></p>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2 mt-1">
                <li>Grade 1 or 2 Cytokine Release Syndrome (CRS)</li>
                <li>Grade 1 or 2 Tumor Flare Reaction</li>
            </ul>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Chemo-free regimens combined with glofitamab displayed high efficacy and good tolerability in R/R DLBCL patients with TP53 gene mutations.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>
                ADC, Antibody-Drug Conjugate; AE, Adverse Event; BTKi, Bruton's Tyrosine Kinase inhibitor; CR, Complete Remission; CRR, Complete Response Rate; CRS, Cytokine Release Syndrome; DLBCL, Diffuse Large B-Cell Lymphoma; EOT, End of Treatment; GCB, Germinal Center B-cell like; IPI, International Prognostic Index; IV, Intravenous; LBCL, Large B-Cell Lymphoma; mg, Milligram; mg/kg, Milligrams per kilogram; NHL, Non-Hodgkin Lymphoma; NGS, Next-Generation Sequencing; ORR, Overall Response Rate; OS, Overall Survival; PD-1, Programmed Death-1; PET-CT, Positron Emission Tomography-Computed Tomography; Pola, Polatuzumab vedotin; Pola-R-CHP, Polatuzumab vedotin + Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; Pts, Patients; R, Rituximab; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; R/R, Relapsed/Refractory; TP53, Tumor Protein 53.
            </p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Zhao X, Liu Z, Xu J, et al. Chemo-free regimens containing Glofitamab are significantly beneficial for relapsed/refractory diffuse large B cell lymphoma patients with TP53 gene mutations: Real-world data from multi-centers in China. Abstract #PB3271 presented at the European Hematology Association (EHA) Congress. 12â€“15 June 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3271 | Abstract Release: 05/14/2025 | Presentation: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    <script>
        function drawStackedBarChartPB3271(containerId, legendContainerId, chartData, chartTitle) {
            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 350;
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = chartWrapper.getBoundingClientRect().width * 0.8;
            }
            containerWidth = Math.max(containerWidth, 250);

            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height");

            const margin = { top: 40, right: 20, bottom: 50, left: 60 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <=0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const categories = ["Response"];
            const stack = d3.stack().keys(chartData.keys);
            const stackedData = stack([chartData.values]);

            const xScale = d3.scaleBand()
                .domain(categories)
                .range([0, chartWidth])
                .padding(0.7);

            const yScale = d3.scaleLinear()
                .domain([0, 100])
                .range([chartHeight, 0]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScale).tickValues([]))
                .select(".domain").remove();

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");

            g.append("g")
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            const color = d3.scaleOrdinal()
                .domain(chartData.keys)
                .range(chartData.colors);

            g.selectAll(".serie")
                .data(stackedData)
                .enter().append("g")
                  .attr("class", "serie")
                .selectAll("rect")
                .data(d => d)
                .enter().append("rect")
                    .attr("x", d => xScale(categories[0]))
                    .attr("y", d => yScale(d[1]))
                    .attr("height", d => Math.max(0, yScale(d[0]) - yScale(d[1])))
                    .attr("width", xScale.bandwidth())
                    .attr("fill", (d, i, nodes) => {
                        const seriesKey = d3.select(nodes[i].parentNode).datum().key;
                        return color(seriesKey);
                    })
                    .attr("rx", 3).attr("ry", 3);

            stackedData.forEach((series) => {
                series.forEach((d) => {
                    const y0 = d[0];
                    const y1 = d[1];
                    const percentage = y1 - y0;
                    if (percentage > 4) {
                        g.append("text")
                            .attr("class", "chart-label")
                            .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                            .attr("y", yScale(y0 + percentage / 2) + 4)
                            .attr("text-anchor", "middle")
                            .style("fill", (series.key === "CR" || series.key === "Other (SD/PD/NR)") ? "white" : "var(--sobi-dark-text)")
                            .style("font-size", "10px")
                            .text(`${percentage.toFixed(1)}%`);
                    }
                });
            });

            if (chartData.orr) {
                 g.append("text")
                    .attr("class", "chart-label")
                    .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                    .attr("y", yScale(chartData.orr) - 12)
                    .attr("text-anchor", "middle")
                    .style("font-weight", "600")
                    .style("fill", "var(--sobi-dark-blue)")
                    .text(`ORR: ${chartData.orr.toFixed(1)}%`);
            }

            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2 + 5)
                .attr("text-anchor", "middle")
                .style("font-size", "13px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendData = chartData.keys.filter(key => chartData.values[key] > 0).map(key => ({
                label: `${key} (${chartData.values[key].toFixed(1)}%)`,
                color: color(key)
            }));

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }

        const glofitamabTp53ResponseData = {
            keys: ["CR", "PR", "Other (SD/PD/NR)"],
            values: {
                CR: 40.0,
                PR: 26.7, // 66.7 (ORR) - 40.0 (CR)
                "Other (SD/PD/NR)": 33.3 // 100 - 66.7 (ORR)
            },
            colors: ["var(--sobi-teal)", "var(--sobi-yellow)", "var(--sobi-medium-gray-text)"],
            orr: 66.7
        };

        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawGlofitamabTp53Chart = debounce(() => drawStackedBarChartPB3271("#glofitamabTp53ResponseChart", "#glofitamabTp53ResponseLegend", glofitamabTp53ResponseData, "Response at End of 6th Cycle (N=15)"), 250);

        window.addEventListener('resize', debouncedDrawGlofitamabTp53Chart);
        document.addEventListener('DOMContentLoaded', debouncedDrawGlofitamabTp53Chart);

        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawGlofitamabTp53Chart, 0);
        }
    </script>
</body>
</html>